secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009175
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio prioritizes ABI-4334, pauses ABI-H3733 on chronic toxicology finding; Q4 2022 net loss $93.1M
--------------------------------------------------------------------------------

- Phase 1a for ABI-4334 complete for single-dose and 100mg multiple-dose; half-life supports once-daily dosing; 200mg data expected April.
- Phase 1b for ABI-H3733: all 7 HBeAg-negative patients achieved HBV DNA below LLOQ by day 21; chronic toxicology in one species halted program.
- Net loss $93.1M ($1.92/share) for FY2022 vs $129.9M ($3.00/share) in 2021; cash $91.6M as of Dec 31, 2022, funding into mid-2024.
- Second development candidate nomination expected in 2023; IND/CTA for herpesvirus candidate ABI-5366 planned for first half 2024.
- CEO Jason Okazaki appointed as previously reported; no new leadership change in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/0000950170-23-009175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/asmb-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer